FAQ: Nutriband Inc.'s AVERSA™ Technology and Its Role in Combating the Opioid Crisis
Summary
What is AVERSA™ technology?
AVERSA™ is a transdermal abuse-deterrent technology developed by Nutriband Inc. designed to prevent misuse, abuse, and accidental exposure of transdermal drugs with abuse potential, such as fentanyl.
Why is Nutriband’s AVERSA™ technology significant?
Given the ongoing opioid crisis in the U.S., with over 100,000 Americans dying annually from drug overdoses, AVERSA™ technology represents a critical innovation in enhancing drug safety by preventing abuse at the product level.
How does AVERSA™ technology work?
While the content does not detail the mechanism, AVERSA™ technology is designed to deter abuse of transdermal drugs, suggesting it may incorporate features that prevent extraction or misuse of the drug.
Who is affected by the opioid crisis?
The opioid crisis affects millions of Americans, with a significant proportion of overdose deaths linked to synthetic opioids like fentanyl, highlighting the need for solutions like AVERSA™ technology.
Where is Nutriband’s technology applicable?
Nutriband’s AVERSA™ technology is applicable in the U.S., where the company has recently expanded its domestic IP coverage with a new patent.
What are the implications of Nutriband’s new patent?
The new U.S. patent for AVERSA™ technology strengthens Nutriband’s intellectual property portfolio, potentially enhancing drug safety across multiple therapeutic categories and contributing to the fight against the opioid crisis.
How can I learn more about Nutriband Inc. and its developments?
For the latest news and updates on Nutriband Inc. (NASDAQ: NTRB), visit the company’s newsroom at https://ibn.fm/NTRB.
This story is based on an article that was registered on the blockchain. The original source content used for this article is located at InvestorBrandNetwork (IBN)
Article Control ID: 88653